J. Kreuzer
About
In The Last Decade
J. Kreuzer
26 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 92
- Molecular Biology 409
- Immunology 331
- Surgery 281
- Physiology 249
- Cardiology and Cardiovascular Medicine 181
Countries citing papers authored by J. Kreuzer
This map shows the geographic impact of J. Kreuzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Kreuzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Kreuzer more than expected).
Fields of papers citing papers by J. Kreuzer
This network shows the impact of papers produced by J. Kreuzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Kreuzer. The network helps show where J. Kreuzer may publish in the future.
Co-authorship network of co-authors of J. Kreuzer
This figure shows the co-authorship network connecting the top 25 collaborators of J. Kreuzer. A scholar is included among the top collaborators of J. Kreuzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Kreuzer. J. Kreuzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions | 2 |
| 2 | Initial experience with idarucizumab in dabigatran-treated patients requiring emergency surgery or interventon: interim results from the RE-VERSE AD study | 5 |
| 3 | 1 | |
| 4 | 3 | |
| 5 | 26 | |
| 6 | 319 | |
| 7 | 30 | |
| 8 | 4 | |
| 9 | 33 | |
| 10 | 87 | |
| 11 | 3 | |
| 12 | 1 | |
| 13 | Effects of HMG-CoA reductase inhibition on PDGF- and angiotensin II- mediated signal transduction: suppression of c-Jun and c-Fos in human smooth muscle cells in vitro. | 16 |
| 14 | 22 | |
| 15 | 25 | |
| 16 | 5 | |
| 17 | 2 | |
| 18 | 222 | |
| 19 | 59 | |
| 20 | [Removal of embolized central venous catheters and pacemaker probes using a Judkin catheter without risk]. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.